BioSpace News Archive

OncoImmune’s SACCOVID ™ (CD24Fc) Exhibits Superb Therapeutic Efficacy—A Potential Breakthrough in Treating Severe and Critical COVID-19

Veracyte, Inc . (Nasdaq: VCYT) announced today that the Centers for Medicare and Medicaid Services (CMS) has approved new Advanced Diagnostic Laboratory Test (ADLT) status for the Envisia ® Genomic Classifier. The determination confirms that the Envisia classifier meets the criteria for ADLT status under the Protecting Access to Medicare Act of 2014 (PAMA), which is reserved for innovative products that pr

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced upcoming presentations

CURE Pharmaceutical Holdings (OTC: CURR) today announced its definitive agreement to acquire Sera Labs, Inc. The closing is anticipated to occur in early October. As previously announced, the transaction consists of an up-front payment of $20 million, of which $1 million was paid in cash and $19 million has been allocated in CURE stock at a valuat

FH Ortho Inc, a long standing, well respected manufacturer of innovative orthopedic devices proudly announces the U.S. launch of the Arrow Prime Advanced Instrumentation for shoulder arthroplasty.

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced it will host a key opinion leader (KOL) call on oral tebipenem HBr for the treatment of complicated urinary tract infections on Wednesday, September 30, 2020

Fresenius Medical Care, the world’s leading provider of products and services for people with chronic kidney failure, today announced publication of its 2020 Global Annual Medical Report. Titled “The Power of Ideas: Ingenuity, Optimism, and the Future of Global Healthcare,” it advances the worldwide conversation about the contin

Acceligen, a Recombinetics Inc. company, today announced that it received a grant from the Bill & Melinda Gates Foundation to develop bovine genetics optimized with traits desirable to smallholder dairy farmers. The breeding program will contribute to more sustainable production by using traits that will increase farmer income

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, announced dosing of the first subject in a Phase 1 clinical trial evaluating the safety, pharmacokinetics and preliminary efficacy of MLE-301, a selective neurokinin 3 receptor (NK3R) antagonist that is being developed for the treatment of VMS,

Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for ANK-700, an antigen-specific drug candidate for the treatment of multiple sclerosis (MS).